Capricor Therapeutics Investors Offered Lead Role in Securities Lawsuit
National shareholder rights firm SBS Law is reminding investors of a potential opportunity to lead a class action lawsuit against Capricor Therapeutics, Inc. The company faces allegations of securities law violations.
Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, is notifying investors of a class action lawsuit filed against Capricor Therapeutics, Inc. (NASDAQ: CAPR). The lawsuit alleges violations of federal securities laws, specifically §§10(b) and 20(a).
The litigation targets investors who purchased Capricor securities during a specific class period. SBS Law is seeking an investor to serve as the lead plaintiff in the action. The lead plaintiff role typically involves greater participation in the lawsuit's proceedings and may offer certain advantages.
Allegations in the lawsuit claim that Capricor made materially false or misleading statements or omitted crucial information, thereby artificially inflating the company's stock price. Investors seeking to participate must provide documentation of their transactions and any resulting losses.
SBS Law, which focuses on shareholder litigation, has urged Capricor investors to contact their legal counsel by a specified deadline. Further details regarding the case's timeline and eligibility requirements are available through SBS Law's offices.